Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Cushings Disease Clinical Trial

Official title: Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)

Status Completed

Clinical Trial Summary

This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease. Patients with Cushing's disease and treated with pasireotide s.c. alone and in combination with other therapies will be monitored. For this study, each enrolled patient will be followed up for 3 years after enrollment. Patients who permanently discontinue pasireotide s.c. prior to completing the 3-year observation period will be followed up for 3 months after the last dose of pasireotide s.c.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• ACTH-Secreting Pituitary Adenoma
• Cushings Disease
• Pituitary ACTH Hypersecretion

• NCT number: NCT02310269
• Study type: Observational
• Source: RECORDATI GROUP
• Status: Completed
• Start date: March 28, 2013
• Completion date: July 10, 2023